Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial
Terada et al., eClinicalMedicine, doi:10.1016/j.eclinm.2022.101484
https://c19early.org/terada.html